Abstract:Abstract We present a rare diagnosis in a 41-year-old man referred urgently from the infectious diseases team with a 3-week history of extensive itchy and painful mucocutaneous blistering and ulceration. This initially affected his hands, spreading to involve his limbs and trunk. His oral and genital mucosae were similarly affected. He reported lethargy and weight loss secondary to reduced oral intake but was otherwise systemically well. He had hypertension managed with amlodipine but he had not recently taken any other medications or supplements. He had emigrated to the UK from Ghana 6 months earlier and no contacts were similarly affected. Examination revealed multiple tense vesicles and bullae with crusted erosions scattered across his trunk and limbs on a background of urticated erythema involving approximately 40% of his body surface area. Haemorrhagic bullae were present on his tongue, his labial and buccal mucosa, and his genital mucosa. He had an extensive infection screen. Of note, viral polymerase chain reaction of vesicular fluid was negative and he was noted to have negative varicella zoster virus (VZV) IgG, in keeping with his history of never previously having chickenpox. Histopathology demonstrated subepidermal blistering with neutrophils and a neutrophil-rich superficial perivascular inflammatory infiltrate and small collections of neutrophils in dermal papillae with incipient clefting. Direct immunofluorescence showed linear deposition of IgG and C3 along the basement membrane zone localizing to the base on salt-split skin. Enzyme-linked immunosorbent assay to collagen VII was strongly positive, and it was negative to BP180/230. On the basis of his clinical findings and investigation results, epidermolysis bullosa acquisita (EBA) was diagnosed. After careful consideration and discussion with the patient, the decision was made to delay systemic immunosuppressive treatment until he had completed VZV vaccination. He was initially managed with clobetasol ointment, Trimovate cream (clobetasone butyrate, nystatin and oxytetracycline calcium) and fluticasone mouthwash. He subsequently commenced prednisolone 40 mg daily, with complete resolution of blistering within 1 month, leaving areas of postinflammatory hypopigmentation, scarring and milia. The introduction of dapsone 50 mg daily has enabled him to gradually wean the dose of prednisolone without further flares. EBA is a very rare immunobullous disease characterized by autoantibodies directed against collagen VII. Different clinical phenotypes are recognized, including a mechanobullous phenotype characterized by acral involvement, skin fragility, scarring and milia; an inflammatory phenotype with skin changes resembling pemphigoid; and a mucosal dominant phenotype. His case was complicated by the need to delay systemic immunosuppression to enable VZV vaccination, an important consideration when long-term immunosuppression may be required. Fortunately, our patient has shown an excellent response to dapsone, highlighting the value of this medication in EBA, among other immunobullous diseases.

Childhood epidermolysis bullosa acquisita: Confirmation of diagnosis by skin deficient in Type VII Collagen, enzyme-linked immunosorbent assay, and immunoblotting

Epidermolysis bullosa acquisita: what's new?

Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions

Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases

Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen

Detection of anti‐type VII collagen IgE antibodies in epidermolysis bullosa acquisita

Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita

Case of epidermolysis bullosa acquisita with concomitant anti-laminin-332 antibodies

Clinical Features of Paediatric Inflammatory Epidermolysis Bullosa Acquisita: A Case Series Study

Epidermolysis Bullosa Acquisita-Current and Emerging Treatments

Epidermolysis bullosa acquisita antigen and the carboxy terminus of type VII collagen have a common immunolocalization to anchoring fibrils and lamina densa of basement membrane

A case of pretibial dystrophic epidermolysis bullosa: decreased expression of the non-helical domain of type VII collagen molecule

Generalized epidermolysis bullosa acquisita

Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease

A case of epidermolysis bullosa acquisita with unusual clinical features

Prevalence of specific anti-skin autoantibodies in a cohort of patients with inherited epidermolysis bullosa

[Clinical, histopathologic, immunofluorescent and ultrastructural estimation of 2 cases of epidermolysis bullosa acquisita]

[Acquired epidermolysis bullosa with a highly varied clinical picture and successful treatment with mycophenolate mofetil]

DP15 A rare immunobullous diagnosis in a varicella zoster-naive patient

C-type lectin receptor expression is a hallmark of neutrophils infiltrating the skin in epidermolysis bullosa acquisita

Patients suffering from dystrophic epidermolysis bullosa are prone to developing autoantibodies against skin proteins: A longitudinal confirmational study